<SEC-DOCUMENT>0001437749-24-009820.txt : 20240328
<SEC-HEADER>0001437749-24-009820.hdr.sgml : 20240328
<ACCEPTANCE-DATETIME>20240328160719
ACCESSION NUMBER:		0001437749-24-009820
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20240326
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240328
DATE AS OF CHANGE:		20240328

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYADIC INTERNATIONAL INC
		CENTRAL INDEX KEY:			0001213809
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				450486747
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32513
		FILM NUMBER:		24798881

	BUSINESS ADDRESS:	
		STREET 1:		1044 NORTH U.S. HIGHWAY ONE
		STREET 2:		SUITE 201
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477
		BUSINESS PHONE:		561-743-8333

	MAIL ADDRESS:	
		STREET 1:		1044 NORTH U.S. HIGHWAY ONE
		STREET 2:		SUITE 201
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CCP WORLDWIDE INC
		DATE OF NAME CHANGE:	20030110
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>dyai20231121_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:dyai="http://www.dyai.com/20240326"><head>
	<title>dyai20231121_8k.htm</title>
	<!-- Generated by ThunderDome Portal - 3/28/2024 12:10:48 PM -->
<meta http-equiv="Content-Type" content="text/html"/></head>
<body class="vsc-initialized" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20248K" name="dei:AmendmentFlag" id="ixv-321">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20248K" name="dei:EntityCentralIndexKey" id="ixv-322">0001213809</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="dyai-20240326.xsd" xlink:type="simple"/>
</ix:references>
<ix:resources>
<xbrli:context id="d20248K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2024-03-26</xbrli:startDate>
<xbrli:endDate>2024-03-26</xbrli:endDate>
</xbrli:period>
</xbrli:context>



</ix:resources>
</ix:header>
</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:center;"><b>UNITED STATES</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:center;"><b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Washington, D.C. 20549</b></div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tbody><tr>
			<td colspan="3" style="vertical-align: bottom; width: 33%;">&#160;</td>
			<td colspan="3" style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 34%;">&#160;</td>
			<td colspan="3" style="vertical-align: bottom; width: 33%;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:center;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:center;"><b>FORM <ix:nonNumeric contextRef="d20248K" name="dei:DocumentType" id="ixv-23"><b><b><b>8-K</b></b></b></ix:nonNumeric></b></div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tbody><tr>
			<td colspan="3" style="vertical-align: bottom; width: 33%;">&#160;</td>
			<td colspan="3" style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 34%;">&#160;</td>
			<td colspan="3" style="vertical-align: bottom; width: 33%;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>CURRENT REPORT</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Pursuant to Section 13 or 15(d) of the</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Securities Exchange Act of 1934</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Date of Report (date of earliest event reported): <ix:nonNumeric contextRef="d20248K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="ixv-43"><b><b><b><span style="text-decoration: underline;">March 26, 2024</span></b></b></b></ix:nonNumeric></b></div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tbody><tr>
			<td colspan="3" style="vertical-align: bottom; width: 33%;">&#160;</td>
			<td colspan="3" style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 34%;">&#160;</td>
			<td colspan="3" style="vertical-align: bottom; width: 33%;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:18pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityRegistrantName" id="ixv-56"><b>Dyadic International, Inc.</b></ix:nonNumeric></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Exact name of registrant as specified in its charter)</div>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="3" style="vertical-align: bottom; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="3" style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 34%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="3" style="vertical-align: bottom; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tbody><tr>
			<td style="vertical-align: middle; width: 33%;">&#160;</td>
			<td style="vertical-align: middle; width: 34%;">&#160;</td>
			<td style="vertical-align: middle; width: 33%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="1" style="vertical-align: top; width: 33%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-75"><b>Delaware</b></ix:nonNumeric></div>

			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(State or other jurisdiction of incorporation or organization)</div>
			</td>
			<td colspan="1" style="vertical-align: top; width: 34%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityFileNumber" id="ixv-80"><b>000-55264</b></ix:nonNumeric></div>

			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Commission File Number)</div>
			</td>
			<td colspan="1" style="vertical-align: top; width: 33%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityTaxIdentificationNumber" id="ixv-85"><b>45-0486747</b></ix:nonNumeric></div>

			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(I.R.S. Employer Identification Number)</div>
			</td>
		</tr>
		<tr>
			<td colspan="1" style="vertical-align: top; width: 33%;">&#160;</td>
			<td colspan="1" style="vertical-align: top; width: 34%;">&#160;</td>
			<td colspan="1" style="vertical-align: top; width: 33%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: bottom; width: 67%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><ix:nonNumeric contextRef="d20248K" name="dei:EntityAddressAddressLine1" id="ixv-96"><b><b>1044 North U.S. Highway One, Suite 201</b></b></ix:nonNumeric><br/>
			<ix:nonNumeric contextRef="d20248K" name="dei:EntityAddressCityOrTown" id="ixv-100"><b><b>Jupiter</b></b></ix:nonNumeric>, <ix:nonNumeric contextRef="d20248K" name="dei:EntityAddressStateOrProvince" id="ixv-103"><b><b>FL</b></b></ix:nonNumeric> <ix:nonNumeric contextRef="d20248K" name="dei:EntityAddressPostalZipCode" id="ixv-106"><b><b>33477</b></b></ix:nonNumeric></b></div>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: bottom; width: 67%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Address of principal executive offices and zip code)</div>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: bottom; width: 67%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: bottom; width: 67%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(<ix:nonNumeric contextRef="d20248K" name="dei:CityAreaCode" id="ixv-118"><b><b>561</b></b></ix:nonNumeric>) <ix:nonNumeric contextRef="d20248K" name="dei:LocalPhoneNumber" id="ixv-121"><b><b>743-8333</b></b></ix:nonNumeric></b></div>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: bottom; width: 67%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Registrant&#8217;s telephone number, including area code)</div>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: bottom; width: 67%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: middle; width: 67%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>N/A</b></div>

			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>&#160;</b>(Former Name or Former Address, if Changed Since Last Report)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tbody><tr>
			<td colspan="3" style="vertical-align:middle;width:7%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="ixv-332">&#9744;</ix:nonNumeric></div>
			</td>
			<td colspan="3" style="vertical-align:middle;width:93%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:middle;width:7%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="ixv-333">&#9744;</ix:nonNumeric></div>
			</td>
			<td colspan="3" style="vertical-align:middle;width:93%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:middle;width:7%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="ixv-334">&#9744;</ix:nonNumeric></div>
			</td>
			<td colspan="3" style="vertical-align:middle;width:93%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:middle;width:7%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="ixv-335">&#9744;</ix:nonNumeric></div>
			</td>
			<td colspan="3" style="vertical-align:middle;width:93%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Securities registered pursuant to Section 12(b) of the Act</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</div>

<table cellpadding="2" cellspacing="0" style="width: 90%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: auto;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="3" style="vertical-align: bottom; width: 33%; border-color: black; border-style: solid; border-width: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Title of each class</div>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 34%; border-top: 1px solid black; border-bottom: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Trading Symbol(s)</div>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 33%; border-color: black; border-style: solid; border-width: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Name of each exchange on which registered</div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="3" style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 33%; border-right: 1px solid black; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><ix:nonNumeric contextRef="d20248K" name="dei:Security12bTitle" id="ixv-336">Common Stock</ix:nonNumeric>, par value $0.001 per share</div>
			</td>
			<td colspan="3" style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 34%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20248K" name="dei:TradingSymbol" id="ixv-337">DYAI</ix:nonNumeric></div>
			</td>
			<td colspan="3" style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 33%; border-right: 1px solid black; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">The <ix:nonNumeric contextRef="d20248K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-338">NASDAQ</ix:nonNumeric> Stock Market LLC</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td colspan="3" style="vertical-align:bottom;width:100%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</div>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:bottom;width:100%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">Emerging growth company <ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-339">&#9744;</ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:bottom;width:100%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Item 2.02. Results of Operations and Financial Condition</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On March 28, 2024, Dyadic International, Inc. (&#8220;Dyadic&#8221;, or the&#160;&#8220;Company&#8221;) issued a press release announcing its financial results for the year ended December 31, 2023&#160;and recent Company progress.&#160;A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference into this Item 2.02.</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The information in this Item 2.02, including the information set forth in Exhibit 99.1, is furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of such section. Such information shall not be incorporated by reference in any filing under the Securities Act of 1933 (the &#8220;Securities Act&#8221;), as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><b>Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b>&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(b)</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">On March 26, 2024, the board of directors (the &#8220;Board&#8221;) of the Company&#160;appointed current member of the Board Patrick Lucy as its Chairman, succeeding the current Chairman Michael Tarnok, effective immediately&#160;Also on March 26, 2024, Mr. Tarnok notified the Board of his decision to retire as a director of the Board, effective at the Company&#8217;s annual meeting to be held in June 2025. Mr. Tarnok intends to continue to serve as a director until such date. Mr. Tarnok&#8217;s decision to retire was not due to any disagreement with the Company on any matter relating to the Company&#8217;s operations, policies or practices.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Also on March 26, 2024, Dr. Barry C. Buckland notified the Board of his decision to retire as a director of the Board, effective at the Company&#8217;s annual meeting to be held in June 2024. Dr. Buckland&#8217;s decision to retire was not due to any disagreement with the Company on any matter relating to the Company&#8217;s operations, policies or practices.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">(c)</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Also on March 26, 2024, the Board appointed Joseph Hazelton, its current Chief Business Officer, to the position of Chief Operating Officer, effective immediately. For the biography of Mr. Hazelton, age 48, see &#8220;Our Executive Officers&#8221; in the Company&#8217;s definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on April 26, 2023.&#160; There are no transactions involving Mr. Hazelton required to be disclosed under Item 404 of Regulation S-K.&#160;To the extent the Company enters into a material compensatory arrangement, or materially amends an existing compensatory arrangement, with Mr. Hazelton in connection with this appointment, the Company will make the required public disclosure with the Securities and Exchange Commission.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><b>Item 7.01. Regulation FD Disclosure.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">On March 28, 2024, the Company issued a press release announcing the aforementioned changes in board and management leadership roles. A copy of the press release is furnished herewith as Exhibit 99.2 and is incorporated herein by reference.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The information in this Item 7.01, including the information set forth in Exhibit 99.2, is furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of such section. Such information shall not be incorporated by reference into any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tbody><tr>
			<td colspan="2" style="vertical-align: middle; width: 20%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Item 9.01. Financial Statements and Exhibits</b></div>
			</td>
			<td style="vertical-align: middle; width: 20%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="1" style="vertical-align: middle; width: 20%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</div>

			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(d) Exhibits</div>

			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</div>
			</td>
			<td colspan="1" style="vertical-align: bottom; width: 80%;">&#160;</td>
			<td style="vertical-align: bottom; width: 80%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="1" style="vertical-align: bottom; width: 20%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Exhibit</b></div>

			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline;"><b>Number</b></span></div>
			</td>
			<td colspan="1" style="vertical-align: bottom; width: 80%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="text-decoration: underline;"><b>Description</b></span></div>
			</td>
			<td style="vertical-align: bottom; width: 80%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="1" style="vertical-align: bottom; width: 20%;">&#160;</td>
			<td colspan="1" style="vertical-align: bottom; width: 80%;">&#160;</td>
			<td style="vertical-align: bottom; width: 80%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="1" style="vertical-align: bottom; width: 20%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">99.1</div>
			</td>
			<td colspan="1" style="vertical-align: bottom; width: 80%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_599795.htm" style="-sec-extract:exhibit;">Dyadic reports 2023 full year results and recent company progress press release dated March 28, 2024</a></div>
			</td>
			<td style="vertical-align: bottom; width: 80%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="1" style="vertical-align: bottom; width: 20%; padding: 0pt; text-align: center;">99.2</td>
			<td colspan="1" style="vertical-align: bottom; width: 80%;"><a href="ex_646031.htm" style="-sec-extract:exhibit;">Dyadic announces change in board and management leadership roles press release dated March 28, 2024</a></td>
			<td style="vertical-align: bottom; width: 80%;">&#160;</td>
		</tr>
		<tr>
			<td style="text-align: center;">104</td>
			<td>Cover page Interactive Data File (embedded within the Inline XBRL document)</td>
			<td>&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>SIGNATURES</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Date:&#160;March 28, 2024</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tbody><tr>
			<td style="vertical-align: bottom; width: 70%;">&#160;</td>
			<td colspan="2" style="vertical-align: bottom; width: 10%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Dyadic International, Inc.</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 70%;">&#160;</td>
			<td colspan="1" style="vertical-align: bottom; width: 10%;">&#160;</td>
			<td colspan="1" style="vertical-align: bottom; width: 20%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 70%;">&#160;</td>
			<td colspan="1" style="vertical-align: bottom; width: 10%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>By:</b></div>
			</td>
			<td colspan="1" style="vertical-align: bottom; width: 20%; border-bottom: 1px solid black;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ Mark A. Emalfarb</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 70%;">&#160;</td>
			<td colspan="1" style="vertical-align: bottom; width: 10%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Name:</b></div>
			</td>
			<td colspan="1" style="vertical-align: bottom; border-bottom: 1px none rgb(0, 0, 0); width: 20%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Mark A. Emalfarb</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 70%;">&#160;</td>
			<td colspan="1" style="vertical-align: top; width: 10%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Title:</b></div>
			</td>
			<td colspan="1" style="vertical-align: bottom; width: 20%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Chief Executive Officer</div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#160;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_599795.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_599795.htm</title>
	<!-- Generated by ThunderDome Portal - 3/28/2024 5:43:37 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body class="vsc-initialized" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;text-indent:92.3%;"><b>Exhibit 99.1</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;text-indent:92.3%;">&nbsp;</p>

<div contenteditable="false" data-hf-endpoint="start" data-hf-html="%3Cdiv%20style%3D%22width%3A%20100%25%3B%22%3E%3Cdiv%20class%3D%22hf-row%22%3E%3Cdiv%20class%3D%22hf-cell%20TOCLink%22%20style%3D%22text-align%3A%20left%3B%20margin%3A%200pt%3B%20width%3A%2099.9%25%3B%20display%3A%20inline-block%3B%22%3E%3C%2Fdiv%3E%3C%2Fdiv%3E%3Cdiv%20class%3D%22hf-row%22%3E%3Cdiv%20class%3D%22hf-cell%22%20style%3D%22font-family%3A%20%26quot%3BTimes%20New%20Roman%26quot%3B%2C%20Times%2C%20serif%3B%20font-size%3A%2010pt%3B%20text-align%3A%20right%3B%20font-weight%3A%20bold%3B%20margin%3A%200pt%3B%20width%3A%2099.9%25%3B%20display%3A%20inline-block%3B%22%3EExhibit%2099.1%3C%2Fdiv%3E%3C%2Fdiv%3E%3C%2Fdiv%3E" data-hf-type="header">&nbsp;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div><img alt="dyadic.jpg" src="dyadic.jpg"></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>DYADIC REPORTS 2023 FULL YEAR RESULTS AND RECENT COMPANY PROGRESS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>Closed a $6.0 million convertible note in a private placement, with a conversion price of $1.79 and no warrants</i></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>Reported positive topline data from First-In-Human Phase 1 trial demonstrated clinical safety and antibody response for DYAI-100 a recombinant protein receptor binding domain (RBD) booster vaccine candidate for protection against COVID-19 infection</i></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>Entered into several fully funded vaccine and antibody projects covering more than twelve targets since announcing</i>&nbsp;<i>topline </i><i>clinical safety data from First-In-Human Phase 1 trial</i></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>Executed a term sheet to utilize our microbial protein production platforms to develop production strains for the production of recombinant serum albumin initially for diagnostic and cell culture applications</i></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>Announced strategic partnership to develop affordable rabies prophylactics and vaccines using C1-cell protein production platform</i></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>Advanced collaboration with Israel Institute for Biological Research (IIBR) targeting bio-threats and emerging disease solutions</i></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>Announced a partnership with Cygnus Technologies to develop and supply a C1 Host Cell Protein ELISA Assay Kit to support batch release testing for C1-based products</i></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>Reported multiple new research and license agreements with Massachusetts General Hospital, bYoRNA (for mRNA), and others </i>&nbsp;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>Expanded collaboration with Phibro/Abic to develop vaccines and treatments for companion and livestock animal diseases</i></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>Published manuscript of preclinical studies on C1 produced monoclonal antibody in non-human primate and hamsters in prestigious peer-reviewed journal Nature Communications </i></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>Cash and investment grade securities of $13.3m, including the $6.0 million convertible note financing</i></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>Changes in board and management leadership roles have been reported in a separate press release this morning</i></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>Financial results and business update conference call scheduled for 5:00 pm ET today</i></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>JUPITER, FL / March 28, 2024 (GLOBAL NEWSWIRE) </b>Dyadic International, Inc. (&#8220;Dyadic&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, or the &#8220;Company&#8221;) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness, today announced its financial results for the year end 2023 and highlighted recent Company progress.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8220;In 2023, Dyadic achieved significant milestones in unlocking the potential of its microbial platforms. One of the highlights was the successful completion of a Phase 1 clinical trial, with positive topline data affirming the safety of Dyadic&#8217;s C1 platform in humans,&#8221; said Mark Emalfarb, Dyadic&#8217;s President and Chief Executive Officer. &#8220;We believe this milestone not only establishes the safety of our platform but also lays a solid foundation for C1 technology&#8217;s future applications in human and animal vaccines and therapeutics. Additionally, our progress made across pharmaceutical and non-pharmaceutical market segments, including human health, animal health, and alternative proteins, underscores Dyadic&#8217;s commitment to innovation and its ability to address diverse areas of need within the biotechnology and food industries. We are grateful for the collaborative efforts of our partners and the dedication of our management team and staff providing invaluable contributions to Dyadic&#8217;s success. Dyadic&#8217;s achievements in 2023 reflect our commitment to advancing our microbial platforms for various applications and its dedication to improving human and animal health while also addressing the challenges of sustainable food production.&#8221;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Mr. Emalfarb continued, &#8220;As we move forward into 2024, our company remains committed to advancing the Dapibus&#8482; platform, specifically tailored for non-pharmaceutical applications in sectors including food, nutrition, health, and wellness. To achieve this objective, we have refined our business development strategies, concentrating on core areas where our technologies can make the most significant impact in the shortest amount of time. This approach involves targeting multiple core verticals simultaneously and exploring new opportunities that align with our overall strategy.&#8221;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8220;In addition to operational advancements, we also strengthened our financial position with the issuance of $6.0 million in convertible notes which will be used to accelerate and exploit our strategic objective of near-term revenue generating products and opportunities for pharmaceutical and non-pharmaceutical applications. We believe that we are well-positioned, both financially and scientifically, to execute our strategic plan with enhanced capabilities and resources. We are excited about the prospects ahead and remain dedicated to delivering value to our customers and stakeholders.&#8221; Mr. Emalfarb concluded.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Dyadic is committed to empowering its partners and collaborators in the development of effective antigens, antibodies and other therapeutic proteins for the prevention, diagnosis, and treatments worldwide. Through an enhanced global outreach strategy, Dyadic is actively advancing its proprietary microbial platform technology to develop products such as recombinant human and bovine albumin, alongside biologic vaccines, antibodies, and other biopharmaceutical solutions. By building a robust pipeline of opportunities, Dyadic believes it can significantly impact global health, fostering a brighter and healthier future through innovation and strategic collaboration.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Recent Company Progress </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><u>Corporate Events</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On March 8, 2024, the Company issued an aggregate principal amount of $6.0 million of its 8.0% Senior Secured Convertible Promissory Notes due March 8, 2027 (the &#8220;Convertible Notes&#8221;) in a private placement in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended. The purchasers of the Convertible Notes include immediate family members and family trusts related to Mark Emalfarb, our President and Chief Executive Officer and a member of our Board of Directors, including The Francisco Trust, an existing holder of more than 5% of the Company&#8217;s outstanding common stock.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company announced changes in the leadership roles of the Board and senior management team. Details of these changes are included in a separate press release issued this morning, March 28, 2024.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="width: 100%;">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: 99.9%; display: inline-block;">&nbsp;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">Exhibit 99.1</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><u>DYAI-100 Phase 1 Clinical Trial </u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">DYAI-100, a C1-SARS-CoV-2 recombinant protein RBD vaccine candidate, is the first C1-expressed protein tested in humans. The Phase 1 randomized, double-blind, placebo-controlled trial was designed as a first-in-human trial to assess the clinical safety and antibody response of DYAI-100, produced using the C1 platform and administered as a booster vaccine at two single dose levels in healthy volunteers. Following the regulatory clearance from the South African Health Products Regulatory Authority (SAHPRA), the trial was initiated in 1Q 2023 with the last patient visit occurring in 3Q 2023. On November 29, 2023, the Company announced the top-line safety results, indicating that the study has met its primary endpoint that both the low and high dose levels of the vaccine are safe and well tolerated among participants. Additionally, the vaccine has been shown to induce immune responses at both dose levels, suggesting its potential efficacy in generating protective immunity against the target virus.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><u>Biopharmaceutical Programs</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On March 25, 2024, the Company entered into a funded research collaboration with a top ten pharmaceutical company to develop a vaccine antigen and a monoclonal antibody produced from the C1 technology.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On March 15, 2024, the Company expanded its collaboration with Phibro Animal Health/Abic Biological Laboratories Ltd to develop vaccines and treatments for companion and livestock animal diseases.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In March 2024, a manuscript of preclinical studies on C1 produced monoclonal antibody in non-human primates and hamsters was published in prestigious peer-reviewed journal Nature Communications. A non-human primate challenge study completed dosing of a C1 produced COVID-19 monoclonal antibody (mAb) that had previously demonstrated broad neutralization and protection against Omicron (BA.1 and BA.2) and the other earlier variants of concern in hamsters. Preliminary results obtained from the challenge study with the SARS-CoV-2 Delta virus on non-human primates demonstrated potential high protection. This was the first time a C1-produced monoclonal antibody was used in a non-human primate study validating the safety and efficacy of a C1 produced antibody for infectious diseases.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">At the NIIMBL conference in February 2024, the Company showcased our project data and research results generated from the NIIMBL Grant received by the Company under the previously announced White House&#8217;s American Rescue Plan.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On February 28, 2024, the Company&#8217;s Dutch subsidiary, Dyadic Nederland BV, entered into a strategic partnership agreement and collaboration with Rabian BV (&#8220;Rabian&#8221;), a Dutch innovative SME founded by experienced entrepreneurs and vaccine scientists. Awarded by Eurostars for the AVATAR project, a part of the European Partnership on Innovative SMEs, and co-funded by the European Union through Horizon Europe. Rabian will use the total funding of approximately &#1028;1.7 million leveraging its expertise in virology to develop a rabies vaccine using Dyadic&#8217;s C1 protein production platform to tackle the challenges posed by rabies, particularly in lower- and middle-income countries. Dyadic is expected to receive an equity stake in Rabian, fully funded research and development costs, and specified product milestones and royalties upon commercialization.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On February 21, 2024, the Company announced it has advanced its collaboration with the Israel Institute for Biological Research (IIBR) and its commercial arm Life Science Research Israel (LSRI), to target emerging disease solutions. This partnership aims to leverage Dyadic&#8217;s expertise in microbial platforms for flexible scale protein bioproduction and the IIBR&#8217;s antibodies and antigens discovery capabilities to develop and manufacture innovative solutions for addressing emerging diseases and potential bio-threats. Through this collaboration, both parties are working towards the development of effective treatments and vaccines to combat global health challenges with the intention of future commercialization (to date, the framework is non-binding and subject to the execution of a binding agreement to be negotiated by the parties) through collaborative out-licensing initiatives.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On February 13, 2024, the Company announced a strategic partnership with Cygnus Technologies&#174;, part of Maravai LifeSciences&#174;&nbsp;(Nasdaq: MRVI), which has developed the C1 Host Cell Protein ELISA Kit for the quality release of products produced using Dyadic&#8217;s protein expression platforms.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On February 6, 2024, the Company announced it has signed a fully funded evaluation agreement including a commercial option with an undisclosed leading global biopharmaceutical company to design and produce recombinant proteins using Dyadic&#8217;s C1 microbial protein production platform.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On October 25, 2023, the Company announced that it has entered into a new research collaboration with the Vaccine and Immunotherapy Center (&#8220;VIC&#8221;) at Massachusetts General Hospital to express vaccine antigens for influenza A and other infectious diseases, as part of a US $5.88 million award from the Department of Defense (&#8220;DoD&#8221;).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On September 26, 2023, the Company entered into a development and commercialization agreement with bYoRNA combining bYoRNA&#8217;s novel eukaryotic &#8220;bio&#8221;&nbsp;RNA platform with Dyadic&#8217;s industrially proven C1 protein production platform to provide the pharmaceutical industry with a potentially more cost-efficient platform for manufacturing large quantities of lower cost mRNA, enabling access to mRNA vaccines and drugs to a broader global population.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="width: 100%;">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: 99.9%; display: inline-block;">&nbsp;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">Exhibit 99.1</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><u>Non-pharmaceutical Programs</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Dyadic is advancing a pipeline of differentiated product candidates that leverage its microbial protein production platforms, including Dapibus&#8482; which have demonstrated the ability and efficiency to enable the rapid development and large-scale manufacture of proteins at low cost in a wide range of non-pharmaceutical applications and commercial use.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Cell Culture Media Products</b></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">o</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Recombinant Serum Albumin: In March 2024, the Company executed a term sheet with a large global albumin manufacturer and distributor to develop and license Dyadic&#8217;s recombinant serum albumin initially for diagnostic and research-grade purposes. The Company&#8217;s animal-free recombinant serum albumin projects were initiated in late 2022 using Dyadic pharmaceutical cell lines for use in potential therapeutic, product development, research, and/or diagnostic human and animal pharmaceutical applications. Animal-free recombinant serum albumin projects were initiated for use in potential non-pharmaceutical applications such as a component of cell culture media in nutrition, health, and food. The Company has completed the initial analysis of its recombinant albumin products and has Certificates of Analysis for recombinant human and bovine albumin that demonstrate comparability to reference standards used in the testing.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">o</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">In March 2024, the Company entered into a co-promotion agreement with Biftek Co. for the promotion of growth media supplement for cell culture.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">o</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The Company is undergoing a project to produce recombinant transferrin for use in cell culture media for the alternative protein industry, and initial expression in our microbial platform was successful.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">o</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The Company is currently sampling recombinant bovine albumin for application testing as growth media for the cultured meat industry.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Non-animal Dairy Products</b></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">o</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">In September 2023, the Company entered into a development and exclusive license agreement to commercialize certain non-animal dairy enzymes used in the production of food products using Dapibus&#8482;&nbsp;and received an upfront payment of $0.6 million in October 2023. The Company believes it has achieved the specified target yield level required for a milestone payment.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">o</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The Company has developed a highly productive strain and is actively sampling recombinant alpha-lactalbumin, a whey protein, with interested collaborators.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">o</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The Company has initiated a beta-lactoglobulin animal-free recombinant whey protein project in early 2024.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">o</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The Company is undergoing a recombinant lactoferrin project, expected to begin sampling the product in the late second or early third quarter of 2024.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">o</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The Company has expressed 4 casein proteins and is in active discussions with potential interested collaborators.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Bio Industrial Products</b></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">o</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The Company has developed a number of enzymes that have the potential for use in multiple industries, such as nutrition, biofuels and biorefining.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Financial Highlights</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash Position: </b>As of December 31, 2023, cash, cash equivalents, and the carrying value of investment-grade securities, including accrued interest, were approximately $7.3 million compared to $12.7 million on December 31, 2022. For the year ended December 31, 2023, the Company received a total of approximately $1.3 million in connection with the sale of Alphazyme LLC. On March 8, 2024, the Company raised $6.0 million in a private placement of convertible notes from existing shareholders.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Revenue: </b>Total revenue for the year ended December 31, 2023, decreased to approximately $2,899,000 compared to $2,930,000 for the year ended December 31, 2022. The decrease in revenue was due to higher individual contract amounts on certain research funding during 2022.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cost of Revenue: </b>Cost of research and development revenue for the year ended December 31, 2023, decreased to approximately $1,976,000 compared to $2,123,000 for the year ended December 31, 2022. The decrease in cost of revenue was due to higher individual contract amounts on certain research funding during 2022.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>R&amp;D Expenses: </b>Research and development expenses for the year ended December 31, 2023, decreased to approximately $3,297,000 compared to $4,501,000 for the year ended December 31, 2022. The decrease primarily reflected the winding down of activities related to the Company&#8217;s Phase 1 clinical trial of DYAI-100 COVID-19 vaccine candidate.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>G&amp;A Expenses: </b>General and administrative expenses for the year ended December 31, 2023, decreased to approximately $5,817,000 compared to $6,422,000 for the year ended December 31, 2022. The decrease principally reflected a decrease in management incentives of $466,000, business development and investor relations costs of</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">$219,000, and legal expenses of $39,000, partially offset by increases in insurance premiums of $96,000, and other increases of $24,000.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Interest Income: </b>Interest income for the year ended December 31, 2023, increased to approximately $417,000 compared to $180,000 for the year ended December 31, 2022. The increase was primarily due to an increase in interest rates and yield on the Company&#8217;s investment-grade securities, which are classified as held-to-maturity.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Other Income: </b>For the year ended December 31, 2023, the Company had a gain of approximately $1,018,000 from the sale of the Company&#8217;s equity interest in Alphazyme, LLC. For the year ended December 31, 2022, the Company received a settlement payment of $250,000&nbsp;from the termination of a proposed license and collaboration.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Net Loss: </b>Net loss for the year ended December 31, 2023, was approximately $6.8 million, or $(0.24) per share, compared to a net loss of $9.7 million, or $(0.34) per share, for the year ended December 31, 2022.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="width: 100%;">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: 99.9%; display: inline-block;">&nbsp;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">Exhibit 99.1</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Conference Call Information</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Date: Thursday, March 28, 2024 Time: 5:00 p.m. Eastern Time</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Dial-in numbers: Toll Free: 877-407-0784 International: 201-689-8560</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Conference ID: 13743567</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1650830&amp;tp_key=065a3e040c</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">An archive of the webcast will be available within 24 hours after completion of the live event and will be accessible on the Investor Relations section of the Company&#8217;s website at www.dyadic.com. To access the replay of the webcast, please follow the webcast link above.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>About Dyadic International, Inc.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Dyadic International, Inc. is a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Dyadic&#8217;s gene expression and protein production platforms are based on the highly productive and scalable fungus <i>Thermothelomyces heterothallica </i>(<i>formerly Myceliophthora thermophila). </i>Our lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is currently used to speed development, lower production costs, and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. Dyadic has also developed the DapibusTM filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">With a passion to enable our partners and collaborators to develop effective preventative and therapeutic treatments in both developed and emerging countries, Dyadic is building an active pipeline by advancing its proprietary microbial platform technologies, including our lead asset DYAI-100 COVID-19 vaccine candidate, as well as other biologic vaccines, antibodies, and other biological products.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">To learn more about Dyadic, please visit http://www.dyadic.com<u>.</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Safe Harbor Regarding Forward-Looking Statements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, including those regarding Dyadic International&#8217;s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Forward-looking statements generally can be identified by use of the words &#8220;expect,&#8221; &#8220;should,&#8221; &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;will,&#8221; &#8220;project,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;potential,&#8221; or &#8220;continue&#8221; and other similar terms or variations of them or similar terminology. Forward-looking statements involve many risks, uncertainties or other factors beyond Dyadic&#8217;s control. These factors include, but are not limited to, the following: (i) our history of net losses; (ii) market and regulatory acceptance of our microbial protein production platforms and other technologies; (iii) competition, including from alternative technologies; (iv) the results of nonclinical studies and clinical trials; (v) our capital needs; (vi) changes in global economic and financial conditions; (vii) our reliance on information technology; (viii) our dependence on third parties; (ix) government regulations and environmental, social and governance issues; and (x) intellectual property risks.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled &#8220;Risk Factors&#8221; in Dyadic&#8217;s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic&#8217;s periodic filings with the SEC, which are accessible on the SEC&#8217;s website and at www.dyadic.com<u>.</u> All forward-looking statements speak only as of the date made, and except as required by applicable law, Dyadic assumes no obligation to publicly update any such forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in our expectations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Contact:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Dyadic International, Inc.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Ping W. Rawson</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Chief Financial Officer Phone: (561) 743-8333</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Email: ir@dyadic.com</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;text-indent:92.3%;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="width: 100%;">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: 99.9%; display: inline-block;">&nbsp;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">Exhibit 99.1</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>CONSOLIDATED STATEMENTS OF OPERATIONS </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" data-tbledgar="true" data-tblname="97362" data-tblv="39" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Years Ended December 31,</b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>2023</b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>2022</b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Revenues:</b></p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Research and development revenue</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,545,865</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,683,244</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">
			<p style="margin: 0pt; text-indent: 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">License revenue</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">352,941</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">247,059</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;">
			<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Total revenue</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">2,898,806</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">2,930,303</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Costs and expenses:</b></p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Costs of research and development revenue</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,975,849</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,123,193</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Research and development</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,297,266</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,501,365</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">General and administrative</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,817,013</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,421,505</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Foreign currency exchange loss</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">38,417</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">49,918</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Total costs and expenses</b></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,128,545</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,095,981</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Loss from operations</b></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(8,229,739</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(10,165,678</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">
			<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>Other income:</b></p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Interest income</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">416,686</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">180,420</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">
			<p style="margin: 0pt; text-indent: 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Gain on sale of Alphazyme</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1,017,592</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Other income</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">250,000</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;"><b>Total other income</b></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,434,278</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">430,420</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Net loss</b></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(6,795,461</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(9,735,258</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td>&nbsp;</td>
			<td id=".lead.B2" style="padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.B2" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.B2" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".trail.B2" style="padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.B3" style="padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.B3" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.B3" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".trail.B3" style="padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Basic and diluted net loss per common share</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(0.24</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(0.34</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Basic and diluted weighted-average common shares outstanding</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28,798,833</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28,364,482</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">See Notes to&nbsp;Consolidated Financial Statements in&nbsp;Dyadic&#8217;s Annual Report on Form 10-K filed with Securities and Exchange Commission on <a data-tblloc="18x1" data-tblname="118522" data-tblv="39" id="led118522F20212161615898994373">March 28, 2024</a>.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="width: 100%;">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: 99.9%; display: inline-block;">&nbsp;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">Exhibit 99.1</div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;text-indent:92.3%;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>CONSOLIDATED BALANCE SHEETS</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" data-tbledgar="true" data-tblname="97360" data-tblv="39" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>December 31,</b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>2023</b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>2022</b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Assets</b></p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Current assets:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Cash and cash equivalents</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,515,028</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,794,272</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Short-term investment securities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">748,290</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,847,270</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Interest receivable</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,083</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">58,285</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Accounts receivable</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">466,159</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">330,001</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Prepaid expenses and other current assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">327,775</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">392,236</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Total current assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,067,335</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,422,064</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Non-current assets:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">
			<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Operating lease right-of-use asset, net</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">141,439</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Investment in Alphazyme</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">284,709</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Other assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,462</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,045</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Total assets</b></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,219,236</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,712,818</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Liabilities and stockholders&#8217; equity</b></p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Current liabilities:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Accounts payable</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">656,445</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,276,313</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Accrued expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,057,164</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">955,081</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Deferred research and development obligations</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">490,113</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40,743</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">
			<p style="margin: 0pt; text-indent: 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Deferred license revenue, current portion</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#8212;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">176,471</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">
			<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Operating lease liability, current portion</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">48,059</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Total current liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,251,781</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,448,608</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">
			<p style="margin: 0pt; text-indent: 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Deferred license revenue, net of current portion</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">176,471</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">
			<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Operating lease liability, net of current portion</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">88,870</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">
			<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>Total liabilities</b></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">2,340,651</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">2,625,079</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Commitments and contingencies (Note 5)</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Stockholders&#8217; equity:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Preferred stock, $.0001 par value:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Authorized shares - 5,000,000; none issued and outstanding</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Common stock, $.001 par value:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Authorized shares - 100,000,000; issued shares - 41,064,563 and 40,816,602, outstanding shares - 28,811,061 and 28,563,100 as of December 31, 2023 and 2022, respectively</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">41,065</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40,817</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Additional paid-in capital</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">105,044,756</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">103,458,697</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Treasury stock, shares held at cost - 12,253,502</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(18,929,915</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(18,929,915</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Accumulated deficit</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(80,277,321</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(73,481,860</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Total stockholders&#8217; equity</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,878,585</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,087,739</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Total liabilities and stockholders&#8217; equity</b></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,219,236</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,712,818</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">See Notes to&nbsp;Consolidated Financial Statements in Dyadic&#8217;s Annual Report on Form 10-K filed with Securities and Exchange Commission on&nbsp;<a data-tblloc="18x1" data-tblname="118522" data-tblv="39" id="led118522F20212161615898966449">March 28, 2024</a>.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ex_646031.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<html><head>
	<title>ex_646031.htm</title>
	<!-- Generated by ThunderDome Portal - 3/28/2024 2:26:35 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.2</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<div><img alt="dyadic.jpg" src="dyadic.jpg"></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Dyadic Announces Change in Board and Management Leadership Roles</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>JUPITER, FL </b>&#8211;<b> March 28, 2024 (GLOBE NEWSWIRE)</b> &#8211; Dyadic International, Inc. (&#8220;Dyadic&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, or the &#8220;Company&#8221;) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness, today announced that Michael Tarnok is stepping down as Chairman of Dyadic&#8217;s board of directors (the &#8220;Board&#8221;) and that current member of the Board Patrick Lucy has been appointed to succeed him, in each case, effective immediately. Mr. Tarnok will continue to serve as a director through the end of his current term, which will end at the Company&#8217;s annual meeting in June 2025, at which time he expects to retire. In addition, Dr. Barry Buckland announced that he is retiring and therefore will not stand for re-election at the Company&#8217;s annual meeting in June 2024. The Board has decided not to fill the vacancy due to Dr. Buckland&#8217;s retirement which will result in a reduction of the size of the Board from seven to six members. Finally, Joseph Hazelton has been appointed Chief Operating Officer, effective immediately, and will oversee the day-to-day operations of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Mr. Lucy joined the Board in January 2021 and has serves on the company&#8217;s Science and Technology Committee. He is currently the President and Chief Executive Officer of RoslinCT US, a privately held cell therapy contract development and manufacturing organization based in Hopkinton, Massachusetts and Edinburgh, Scotland. Mr. Lucy has 33 years of experience in the biotechnology industry, including a founder of Pfenex Inc., a protein expression platform technology company that originated within The Dow Chemical Company (&#8220;Dow&#8221;). He was a member of the leadership team that led the commercial launch of the Pfenex Expression Technology&#8482; platform in 2005 and participated in the spin out of the business from Dow in 2009 via a Series A venture financing. Throughout Pfenex&#8217;s history, Mr. Lucy led business/corporate development and portfolio strategy as Chief Business Officer and was a member of the team that successfully completed Pfenex&#8217;s initial public offering in 2014. During his tenure at Pfenex, Mr. Lucy completed over $1.5 billion dollars of partnership transactions, and Pfenex was ultimately acquired by Ligand Pharmaceuticals in October 2020 for up to $512 million.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">"I am excited to assume the role as Chairman of the Dyadic board of directors. On behalf of the entire Dyadic team, I would like to thank Mike Tarnok for his leadership as Chairman over the past ten years,&#8221; said Mr. Lucy. &#8220;I believe that Dyadic is poised to monetize the many scientific advances we have made with our C1 gene expression system, including the completion of the first Phase 1 clinical study in 2023, and our new Dapibus&#8482; platform that is focused on producing high value proteins for food, nutrition, and wellness. I look forward to working with Mark Emalfarb, our CEO, and Joe Hazelton in his new role as Chief Operating Officer and the rest of our talented management team and Board with a laser focus on maximizing shareholder value.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Mark Emalfarb, Dyadic&#8217;s Chief Executive Officer commented, &#8220;Patrick has been an outstanding board member over the past three years and I am pleased that he has agreed to take on the role as Board Chairman at a pivotal time for Dyadic. We are accelerating commercialization of the C1 and Dapibus platforms for pharmaceutical and nonpharmaceutical applications. Under Michael Tarnok&#8217;s leadership, Dyadic has evolved from the industrial enzyme business and has developed a flexible, safe, and highly efficient platform for the development and production of biologics and we believe we are now poised to deliver impactful advancements that could potentially transform healthcare and food production. I could not be more pleased that Mike has agreed to complete his current term through June 2025, so we can continue to benefit from his expertise and guidance.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Mr. Emalfarb continued, &#8220;Barry has been an invaluable member of our Science and Technology Committee and has contributed greatly to the numerous scientific achievements we have accomplished over the last six years. We will miss him and wish him well in his future endeavors.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Mr. Emalfarb concluded, &#8220;Joe has been instrumental in refocusing the Company on core verticals with shorter-term revenue opportunities, playing a vital role in achieving strategic objectives. His promotion to Chief Operating Officer is well-deserved, and I'm confident he will further enhance Dyadic&#8217;s value by expanding the internal pipeline of high-value biologic products and accelerating the commercialization of assets like alpha-lactalbumin and recombinant human albumin.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8220;I am very excited to take on these additional responsibilities and have a more active role in overall corporate direction and execution of our strategic business plans to accelerate and exploit short-term revenue producing products and opportunities for pharmaceutical and non-pharmaceutical applications. I look forward to expanding our internal pipeline&nbsp;improving&nbsp;our capability to develop more rapid custom solutions for collaborators and hastening the commercialization of current assets,&#8221; said Joe Hazelton, Dyadic&#8217;s new Chief Operating Officer.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>About Dyadic International, Inc.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Dyadic International, Inc., is a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Dyadic&#8217;s gene expression and protein production platforms are based on the highly productive and scalable fungus <i>Thermothelomyces heterothallica </i>(<i>formerly Myceliophthora thermophila). </i>Our lead platform, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is currently used to speed development, lower production costs, and potentially improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. Dyadic has also developed the Dapibus<sup style="vertical-align:top;line-height:120%;">TM</sup><sup style="vertical-align:top;line-height:120%;"> </sup>filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Dyadic is focusing on leveraging its microbial platform technologies for itself and its collaborators in a wide range of applications, including human and animal vaccines, therapeutics, food, nutrition, wellness, and internal biological products.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">To learn more about Dyadic please visit http://www.dyadic.com.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Safe Harbor Regarding Forward-Looking Statements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International&#8217;s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the outcomes of the personnel changes described herein, as well as the success of our protein production platforms. Forward-looking statements generally can be identified by use of the words &#8220;expect,&#8221; &#8220;should,&#8221; &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;will,&#8221; &#8220;project,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;potential,&#8221; or &#8220;continue&#8221; and other similar terms or variations of them or similar terminology. Forward-looking statements involve many risks, uncertainties or other factors beyond Dyadic&#8217;s control. These factors include, but are not limited to, the following: (i) our history of net losses; (ii) market and regulatory acceptance of our microbial protein production platforms and other technologies; (iii) competition, including from alternative technologies; (iv) the results of nonclinical studies and clinical trials; (v) our capital needs; (vi) changes in global economic and financial conditions; (vii) our reliance on information technology; (viii) our dependence on third parties; (ix) government regulations and environmental, social and governance issues; and (x) intellectual property risks. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled &#8220;Risk Factors&#8221; in Dyadic&#8217;s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission (&#8220;SEC&#8221;), as such factors may be updated from time to time in Dyadic&#8217;s periodic filings with the SEC, which are accessible on the SEC&#8217;s website and at www.dyadic.com. All forward-looking statements speak only as of the date made, and except as required by applicable law, Dyadic assumes no obligation to publicly update any such forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in our expectations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Contact:</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Dyadic International, Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Ping W. Rawson</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Chief Financial Officer</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Phone: (561) 743-8333</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Email: </b><b>ir@dyadic.com</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>dyai-20240326.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 3/28/2024 5:39:50 PM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:dyai="http://www.dyai.com/20240326" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.dyai.com/20240326">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dyai-20240326_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dyai-20240326_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dyai-20240326_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.dyai.com/20240326/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="dyai_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>dyai-20240326_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 3/28/2024 5:39:50 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.dyai.com/20240326/role/statement-document-and-entity-information" xlink:href="dyai-20240326.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.dyai.com/20240326/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>dyai-20240326_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 3/28/2024 5:39:50 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>dyai-20240326_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 3/28/2024 5:39:50 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.dyai.com/20240326/role/statement-document-and-entity-information" xlink:href="dyai-20240326.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.dyai.com/20240326/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>dyadic.jpg
<TEXT>
begin 644 dyadic.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !0 &\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_*\H\0?M
MU_!7PGKM[I>J?%SX9Z;J>FSO;7=I=>)[.*>VE0E7C=&D#*RD$$$9!%>KU^!?
M[(7_  3F^'7_  49_P""N'[5GA_XAKKHL?#NOZCJ-H=)OA9R>;)JLT;;CL;<
M-N.,=:[<)AZ=13E4;2BKZ>MC"M4E%I16K/W.^'_QF\)?%G0Y=3\+>)_#WB73
M8#MDN])U*&]@C.,X9XV8 XYP>:I?"K]HGP%\=3??\(3XU\)^+_[,V"\_L75H
M+_[+OW;/,\IFV[MK8SUVGTK\8M9_9_E_X(&?\%>OA'%X'\2:Y>_"WXNR0Z;J
M%IJ#J9&BDN5M9(YBBJDK0R3031R;0PRRGC);H?B?IZ?\$-_^"W^G^+X0ND_!
M#X[&1+[RUV6NG"65?M ( P!:W;)<# XAN' Z&NC^SHM_NY7NKQTWMNO4CZPU
M\2V=G_F?KU\1_P!H_P"'_P 'M?T_2O%GC?PCX9U35AFQL]5U>"SN+P%P@\M)
M&#/\Y"_*#R<=:O?%#XT^$?@CH$6J^,O%'AWPGID\XMH[O6-1BL8))2&81AY&
M4%B%8X'.%/I7Y"_L'>%IO^"QW_!97QG^T#KELUW\,/A#=1V?AB"Y7,<LL186
M"@'CC][>OZ/+"#UI_P#P<07OB+]M/]M[X0?LU>"/*O-2LM.N_$=U"22JW,D,
MS1^8/5+:UE(_Z^!ZTEEZ]M&C*6MKR\NH/$/D<TNMEYG['>&_%.G>,= LM5TF
M^L]3TO4H4N;2\M)EF@NHG 9)$=2596!!!!P0:\UU;]O;X(:#JEU8WWQA^%]G
M>V4SV]Q;S^*;*.6"1&*NC*9,JRL""#R"#7R+_P &TG[3+?&[_@G79^%;Z7.L
M?"W5)-!>)S^]2S?%Q:EAVPLCQ#_KACM7P;_P38_X)H?#7_@H_P#MV?M.:;\1
M!X@6#PKXANKJQ;2+\6;;Y]4OD?>2C;AB-<>G/K1# 04ZJK-I0[>H2Q$K1<%\
M1^\WP^^*WAGXLZ)_:?A7Q#H7B;3=YB^UZ3J$5[!O !*[XV9<X(XSFJ/@_P"/
MG@CXA>,]7\.:!XO\,:WX@\/LRZIIEAJD-Q>:<5?8PFB1BT9#@J=P'(QUK\9_
MA[\%KO\ X(6?\%L/AMX+\)^(]6U#X6_&E+>RGM;^1=[)/,]LHGV*J/+;W/E.
MDH4'9*RGJ<U/V/?VAD_9'_X*!?\ !0_XC&WCGN?"5AJ]];1,/EFN1J\BPHWL
M960'V)JO[-33E3E=637G=VLR?K5FE):WL_NN?K]\;/VW?A#^S?K,.F^//B7X
M'\):E< -'9ZIK,-O<%3T;RV;<%/]X@#WK2\6?M1^!?"7P;_X3]O$6G:EX3D5
M3;ZAI<POHKTLVU5A,6X.2<]#@8)8@ D?D/\ \$GO^"+/A;_@HQ\ =4^.WQYU
MSQ?XD\2_$;4KV2T:TU0VC[8Y6A>ZDD +22/*DFQ#^[1$0;3GCW#_ ()J_P#!
M'#XF_LN^/_BY\/?&FHV>I_ '7+HW/AXIJ8_M3[7%(OD7RP+&T41D@:2*96.)
M-@#1LI(J:N$PT+Q]I[T=]-^]O0J%6I*SY='_ %J?HY\%?C;X?^/_ ('C\0>&
M[F2XL7D,+K+$8Y8) %8HZGH=K*P(R&5E920P-=;7&? CX%Z)^SUX#70-!^UM
M;>:9Y9KJ0/+,^U8P3@*BJL<<<:HBJB)&BJH"BNSKS)6O[NQU!7Y"_P#!$_G_
M (+4?MEX!_Y"%[T'_49FK]>J_"#]J#_@G1\"-;_:R^)WB&X_;:T'P+KNO>)M
M0N]2TF'3GCFTV:2X=WMI'2Y0N8V)'('(SBNS"8C#TX3AB)J',K)OU%]4Q->2
M^K4W-K>RN>G_ /!>G6;;]H3_ (*F?LK_  L\/3Q7WB'3-3AGOXK=P[V(N=0M
M742 ?<(AM)92#@A<'H17TE_P<C?"W1/'/_!+SQ-K6HV<<VI^$-5T[4=*N1P]
MK+)=QVTF#UVM#,ZD=#P>H%?/O_!-KX*_L3_\$_?BC)\0+[]I'PW\1_'_ )4D
M5IJ>I7"VT.FB0;9'BB&\F5ERID=V(4D#&XY^@?\ @H;^UQ^S-^WE^R7XE^%W
M_#17@/PP/$3VCG4@_P!K,'D7,4_^KRF[/E[?O#&<^U6\SPD:M&,*BY8=?G=F
MW]AYBX3<J$KRZ<K_ ,CL_P#@@_\ #?0OA;_P2G^%UQIEK%8MXBTU]?U6<GFY
MNIY',DKM[*J*/18U':OR5^%'_!03X@M_P52^*_[2/@3X1ZY\7_M]W>:/I0AM
M;V6'2;4F.*W;?;Q28<VMNH"G'$K&OT>^%_[3W[//PA_X)PVOP&T;]I_P%%J-
MEX4F\,P>)F3YH3*CH;D6^_[P$APOF=0.:SO^"67Q=_93_P""9'[.=SX%L?VB
MO OBBZU'5YM6O=59OL;7#.L<<:>6"^ D<2*/F.3D\9HIYKA(.K4<E)R=DK]+
MZ_H*619C+DBJ,TE_=>_W'R!_P0>_:-U7X,_\%:O&7A;Q1X5U+X;VGQPANKRW
M\.WT,UL-.NUFDO;9%694=D\LW<:,5&<@5[)_P;NG/_!0K]K\@$C^V6Y _P"H
MOJ5=-^W-?_LS?M:?MG?"SXWZ%^U-X$\$^*?AH]L2A@%]'JBV]V+F)6.^,KC=
M-&?O967VY^7?B'_P3V_9U\7_ !=\7>*M,_;M\->'3XKUB\U5[:RT]X_)$]Q)
M,(BZ72EPGF8!(YQG S74\TP%:,G*JHN22?6S3_R,UD69P:M0F[-_9?7Y'M__
M  5TUBT_:#_X+O?LN>!?#EQ'?ZMX5N["?5EMSO-@3J O&1\=&6WMFD(/(#KZ
MU\]VWP\U+XM_'[_@IMI.CP27%_)IFIW\<*#+R"VU[[4Z@=SLB;BOJ7_@FA\+
M_P!B;_@G3XYN_&K?M%>&?B#\0+J![:/6=2N$@33XY,>;Y$*[B'DZ-([LQ7@%
M06SO?L;>(OV8OV3OVU?C1\7G_:?\!>(D^+\MP[Z.\ @73A->-<E3+O;S1\VS
ME%SU]JA9Q@Z<>2%1/E2MYOFNQO(,QD^:5">K_E>FENQZY_P;D?&G1?B5_P $
MN?!^BZ==P3ZIX&NK[2=3MD<&6W9KN6XA9EZA9(ID96/!YQT./2/V3/\ @K7X
M$_;!_:^^(GP?\,Z1KDFH?#]YV.MQ^5<:/J4$,L<+R1RH^5)F=E4%2&",0U?E
MS^T)^P'^R_?_ !5UC7?@M^V1X8^%VB>)&<7VA&>>6&WC<DM#%)#+$S0<G;%*
M&"@X#8X'U_\ \$Q/%7[%_P#P3 ^&6IZ;H/QX\&>(O$?B!HYM;U^\NEADNQ$#
MY<4<:@B*!-S$)N8Y=B6)(QRXK%9=+GK1JIRELMK/K<UI91FBM!X>22Z\KU_
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I,0VEE"EO!&"2(T10JKSSP !^%7*[XJT4CYN<N:384444R0HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140205913811664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">Dyadic International, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Mar. 26,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">000-55264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">45-0486747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">1044 North U.S. Highway One, Suite 201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Jupiter<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">33477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">743-8333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DYAI<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0001213809<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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ML0(  .(,   -    >&PO<W1Y;&5S+GAM;-U7;6O;,!#^*T(_8&YB:N*1&+9
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M8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0
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M              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( .6 ?%@D'INBK0   /@!   :
M          "  <@1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( .6 ?%AED'F2&0$  ,\#   3              "  :T2  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /<3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="dyai20231121_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyai.com/20240326/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>dyai-20240326.xsd</File>
    <File>dyai-20240326_def.xml</File>
    <File>dyai-20240326_lab.xml</File>
    <File>dyai-20240326_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="dyai20231121_8k.htm">dyai20231121_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "dyai20231121_8k.htm": {
   "nsprefix": "dyai",
   "nsuri": "http://www.dyai.com/20240326",
   "dts": {
    "schema": {
     "local": [
      "dyai-20240326.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "dyai-20240326_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "dyai-20240326_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dyai-20240326_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "dyai20231121_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 26,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.dyai.com/20240326/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d20248K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20231121_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d20248K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dyai20231121_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.dyai.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.dyai.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.dyai.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.dyai.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.dyai.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.dyai.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.dyai.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.dyai.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.dyai.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.dyai.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.dyai.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.dyai.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.dyai.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.dyai.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.dyai.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.dyai.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.dyai.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.dyai.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.dyai.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.dyai.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.dyai.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.dyai.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.dyai.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.dyai.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.dyai.com/20240326/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001437749-24-009820-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-24-009820-xbrl.zip
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M2R+>GN#7<31T]UQ_):IZBC<(5R*69!M8M5%_'V94Y<(7('L1<@RC978A=\=
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M$EF172&[*!)1N[J(UR[%12KRK8Z]FEL,BL&+?%%4Z'\PBY?\%U67Z=K=9%3
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MFQ:,Y'_>_+T+S;O0+$4M+UUHYC,%8)]:)Y<=TCJYOFIU7L4:78-#'5,_(E%
MVLS!= :Q*R00Q-[9=+=(T"-1G[T*: !.+""^@$E/(/BB_@TC#2="D.S]2G7U
M,+T2EZ#/B9MNL1#B.[+IFF=&P>=D,B+L#GH3H9J9NU6?2P_K[!7JW*B.,PZ@
M4]^EHQ%,R_QI>OI:>;LGV@D>*^QJ5F$?HC)(L*+VXS(G$"I-5B<J4L5,$VSL
M@@JG3\J[VP0A.BSAP*-W9?^N[*>E$2:(,"598,2(J(>,()$?)[VU.:3W&;F
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MN C<R3K:=.QHJQ KZ07ADXJ\]#NE(9>*O+.'*MSE]L7Q,(/OFV# X!;3(N-
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MHC5![C-P85GBY=*TZ9/5$?$)5.9ABI1'E9LB,!:]LL*9Z%0!/E."6VI]!00
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MHMZ9!"@7>4;C:JH(.V:H"A3H<VNVP0>8H I$GMGHZ.)*V)>GHX&ZT>NTE]%
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MBCZA$(YC]JCE(G>2&VB?]2R\&"%9Q59U,\$\<[S5$E&%. BO1,5L*F(+@YC
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M9Y[TO\&>(JHW$:D"NO7T"% ;0\$_$',LM,F9#Y2GY-H4S$7;7]^LSI7 W(.
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M/%33"=Y4D2S1E3)6<\)+*V2^4!9:Y")$5A78<%BCAH[P97:L3G?$I8 8<]R
M.XX:Q,SU5,[B,:K=]5KE5]IJ799'Z4P+M_P';4TQ3+59/CH@24/B+^(LP&Y1
M1(2S8:J7*^P$)<CAGXNCPL:2+@IS>#\<8C_WA2019-&)"C<LND?1J,Z[2".M
ME?5M^S9MQI\)_@W>CCUD(PY.3;1@8L@O-70"L#3\/48+0$-'&:PX.)O?Q!82
M6"PATJ'C,G=@R[$^V*YJ%VZA:X*6BE'/7%K)U:,C4 )*G^ ^.D;(!QV/D$:[
MH,,1F(.CS"N2 :GW83P_2Y<*;3'%SI RTQ2Y1@[B ]1NK6"G$/K\<SN"7^#C
MYTBM?V!CU1L?8Z[/'\:;@.[.DGJ@K^C!AA-Q/G$=>-%VJUU_SSK-1J7;:#1>
M8#Q'4U"S=YCT_F^*\3R$L%:6I-$84B25BK2K!()T-6#/K#;>E5DO9=9+F?52
MU*R7)SGY^H21+#O\LW]X<L!.SH#XS_I7)U_/^J? ^,\.JJQ_=L@N?]N_/#D\
MZ5^<'%T^6-S]Z-@.OIY=?CT].>Q?'<%(KN"/+T=G5Y?LZS'[>GYT0:.]9"\[
MK!\KSM='!<RZ*WQT"_4O7@G@K\,QAU<$7IBZB)&I3UN]3J-M)A>O/VTU>LNY
M\'+9\X@C>(\2\44VYXT'VV8+>XOI_WF_R_*%Y ,W"-SI0BGY4[&*I67H<OAI
MJXI!@.IAX\F9T](OPH+ ICN?MMI;ZNM\&J0_ODS:/1FW7!3%BCXK:NWAMMEW
M['4LA[1C-8/A?]_?6@/_Y"?[3\'!Y#M:R.E=AH.0;")"9=G/L8M,G]GT&BUL
MK2Z*?_.'P'SA0V"F#X%9'H+X$&!F_;T(_NEW[%X$_]K<TRRYYTK",=>#4]::
MP"0;W5?BE)&9T%%&UVH(F!^GJ$68 W_G]BVD,[?_0LR:ONC/IX.7_2*>[/WE
M(D$9K\\_!'52GF76L-?15W&CEV_P"S'5U :_Y!=I@Y>S[A?>X.>8]=(-?CMJ
MXO,SO/C_>S/5$^IVB(\[F*&Y8/6^>PD"HE/SK-]>U#JV]GY>?I@6QV&^6^TA
M>Z:QF4:KV3*Z[=:JTP:C=-P;C\\BC\8SKMTRA639H&_5;1NO2%K/^NT'D-;B
M.%Z%M-K=AF$VFZM(JU%XTGHSVJ^>'LPBQ;3S8F'18QWY!7NQA_$)7(Y;>Z>Z
M#K\ LF#5RKRBA'C@B%Y'5*P89*-E&KUFO4#"XK[+^/RRX5&D5J@1O8[H6#%(
ML]DQ:JU>@83'[<OX5HR%6!0JL==;8C]D!,73B84,#N0K"H57Y/[%8O.HHW5[
M7:-;:[\^1W]%UOV*/+I8S!@) D%4&[7&Z_/=EU+&;Z>[??-N+^M=3M&[/99W
MC*%QMR/P+K_=W4ZU-RK/7L[;?T"XBRK[5X-7EG[_TN]?^OTWU^__NFZ?5_#[
M'VCLV3LQOC<U % L#7^ICQ.QTUM&M[G2MGY)-T[IWK\7X13$HX_H^O5> 8R#
M)W7>K[\">\_H;<FT"\NT5:L#LUT 3TW)M-\2TU;-,!JK(_QOE&EOG.J]ND=&
MR;8+R[9URY'Z2I6I9-LEVUZV,=B4I@ZL>]W8]L;IVL>N)V!J&MK#FB-TA$*W
M0N2<367=]Z[%*#B'O_<\0%-IUCM%D )EEN6S$V8!),B]Y]'L&;UZMPA29KUS
M-%\N3JGR;*R%:.4]@I6EO%D7>5.O&W6SB]G]I<PI94[1B+-AU'HMH]==F4F\
M3G+G829/F8[T@^E(FR+F3ZGEGX?(D3.A47]+$;]!(GZ[:YAFS^@TBAG(7X$O
M\+Z4[FLNW;?K-:/>;AGM3B',R@<39BG92\G^-$66"Z]XY%A23:%5<_!72CQ^
M5(E; <;Q8DG*#QW8LZ4N/ZH\\ADR;!]',:\_CA?+>GXDQ;S6"I6!OI6!OI.D
MIPNRZ$TUPPIO7VWM->MMH]TM,^F*9"45WOS9VJMW:T;3K!72IMD@I?HYD4L^
M<VQWX3 ?^URZ(]:W9Q/^W_GK<O,2P^1)!UDW:O6.T>J91>#_)8K)>J.84&<B
M<Z4>7Z*8O!W]/NU_V53E?N-B+'><WS*'HBCVP\9%6<Q6S:C5"F&-E(E[3RQJ
MXB0^-R-S-C>V7WB!@F9%L]$TS-4QS]*M5+J5EGHC&^OH5BI#XQL4&G^YI+<S
MW7%\DX7AW4IC Y3&H1MB1[N<UEA<+/K[SV&[;71Z+:/9+@0.\=WI18T-S7M[
M>C(M@+Q^ )EB:F;+,%MO) NN49 LN.AK#^MKED\U>@IWP!.^;B'1YQ%=VU))
M'X]9F\;3KLW3O6XAI66=&I.]D&JTSWUI*3@G:8>!&#)':TIL)CQFN=,IAC4G
MW-M<W_4;:\VS7:N:*WNGO+(SH51F"JVD$/$T"M%XYS;B*;T)I3>A2"+S1N#!
M%,,*AQGSL<B(39^Y8> '<#^H)ILJ0]^ '][L&AWL:=$H(;>*)$#?@",>**?1
M;AK-[LK,L"+ZXG^"/_G %GL__?2,/:NIZ"$9P6SEUYZ,06=V_Z_0#^1H#B.X
M%(*=N0&\/'#5: Y<A\Q-CBS\6#K<L22WV64 %Q#4UF?247<>SOE06I32T=GU
M6=]Q0KCQ0LQ<+\"LSV/7F\)(*K^RD;11'LA@PBZ%%7HRD$*!J1Q%Z%T'(!ND
M[TN7$D8_<@8#X)5@8-NN]6FKWOU>WXHO.7P*RU2O=UNFF5R]_K35Z*G&Z/ U
M]>NQ63/K9KT-_]?J]KJ]7K/1 4'^A=!Z393(-30*^%[UMDUXMBT?RFMFV=SW
M/VV=?][_=>$ U&KOEKF:]!4ZPW0)1'SV7<=7%TN+;:*N\*D/Y)Z=C"J>>[-X
MT1*VS<X_G_WV)9D#W 'W9?[XZ>,DUH;.^Y^/*OL71_U?*_WCJZ.+'<;M&S[W
M(Z??#IQ^1V0&L\LF0LW*Q*0'K43]LT;_@><6]"O]T\("_')XL70U'S+;JZ\'
MI]+Y=DO54N: Z<_T>M4>S&,H_9G-X0!+QY:.J R CK_M+E^[>P_IZ:N45LF$
M&[T- ]<>/FJ>1]\G<B #O*V^E%+BN3_?D5,32B>X]\QJX]V]&.^3#$ ?-PJU
M'?[9/SPY8"=G<!+.^E<G7\_ZIP;\\Z#*^F>'[/*W_<N3PY/^Q<G191R->ZFQ
M'7P]N_QZ>G+8OSHZ9/O]T_[9P1&[_.7HZ.J%QY+9%Y+#FE=\VJIM,3P"VID9
M_]N?<2O^MSHL(^E<X:.):!##,?<B)2,K17J=1KNV($26\>&%L_/80YBIN*B1
M,Q;TCK>0)'RKKGWX0FUT8$%@TYU/6^VM1.--?7R9O"M @N%J(_SI68VPQ'0@
M/-:H&[=']I4>_@P[MP(4XJUFQ]].^"_4("PF?#--^,OK\#>3\$&;;]R+X)\/
M(> A$<@7YYAFR3%7$HZY'ISRE>M/M<;44:;6"V6Q]7U?!/?)82N;1S[W$,KF
MD<^^P67SR&+JB"_"[0ZH[4' .+&\G9+?K2^_>VELJ9+1O12C>YNZW6NTQ^6^
M:JIHX5_$WZ&\YC;&H#8U8>"M)=VUC5:]9=3,LHJO2,D#;RW[KF5T>E@+^J82
M"4J-=9&?7TY<+Z@$PILRZ5P+/Z 6YWZ<$K"I;/T-Y(%UFEW#[*TLJRWY>)D$
MMEP!Z#8[P+K7K1Y[XU3Q&([5$Y8 -7Q@;VSERQO@UO6:4>N6&;LELWZ8G@TB
MOEMVR'WCG+IO6; (@5]RZK? J9OMME%O%;/E4,FJ"\NJ&PV$JRM$O[]2JWX\
MKS[WQ(S+I*<L.;L52IV5B?1M*@??.(34AMDQ.IVRRVSAA<3&(:0V>J9A-E:V
M^5@GA-3UMQG@([JO>2EF-E',=(U:NV,T&J6@*05-T6BSWC":I@D$6@C$E6*A
M<9=8+#^(Q;(1HOW,=2I6F2E:9HJ6F:)EINB;Z$*W\(K'CF6AG=W6WM>9\'@
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MGH_H7K-X:W&D]4[;:'8*842L5057P:N HWCFO!0MCST[;[3XX DFU.P:M6*
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M<TV+<$"@"A!KG0-ZR'PH$YF\#P49J/8[(G7P6LMX!O.YBV=HSXH>YHHK#WE
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M)16<"B0R6*I Q(%FQ/&N/GF(?K2.<ICR+7J5VM9%@Y A6>$5?NE2[HRX]SN
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MVHKIT-G%=B/7D<]?_?#CV]5J_'>(M_Z#7>S2GZ_"1/B/</\!4$L! A0#%
M  @ Y8!\6!#%A%EG P  ;@T  !$              ( !     &1Y86DM,C R
M-# S,C8N>'-D4$L! A0#%     @ Y8!\6"<\_^;8!   Y2P  !4
M     ( !E@,  &1Y86DM,C R-# S,C9?9&5F+GAM;%!+ 0(4 Q0    ( .6
M?%BD'8NT^04  $,\   5              "  :$(  !D>6%I+3(P,C0P,S(V
M7VQA8BYX;6Q02P$"% ,4    " #E@'Q8'!JU 74$  !]+0  %0
M    @ '-#@  9'EA:2TR,#(T,#,R-E]P<F4N>&UL4$L! A0#%     @ Y8!\
M6 SMY ,O%   #H0  !,              ( !=1,  &1Y86DR,#(S,3$R,5\X
M:RYH=&U02P$"% ,4    " #E@'Q89NWJL.XV  "62P( #0
M@ '5)P  97A?-3DY-SDU+FAT;5!+ 0(4 Q0    ( .6 ?%C@D0MP7A$  (L[
M   -              "  >Y>  !E>%\V-#8P,S$N:'1M4$L%!@     '  <
*OP$  '=P      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>dyai20231121_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="dyai-20240326.xsd" xlink:type="simple"/>
    <context id="d20248K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <startDate>2024-03-26</startDate>
            <endDate>2024-03-26</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20248K" id="ixv-321">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20248K" id="ixv-322">0001213809</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20248K" id="ixv-23">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20248K" id="ixv-43">2024-03-26</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20248K" id="ixv-56">Dyadic International, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20248K" id="ixv-75">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20248K" id="ixv-80">000-55264</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20248K" id="ixv-85">45-0486747</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20248K" id="ixv-96">1044 North U.S. Highway One, Suite 201</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d20248K" id="ixv-100">Jupiter</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20248K" id="ixv-103">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20248K" id="ixv-106">33477</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20248K" id="ixv-118">561</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20248K" id="ixv-121">743-8333</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20248K" id="ixv-332">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20248K" id="ixv-333">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20248K" id="ixv-334">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20248K" id="ixv-335">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="d20248K" id="ixv-336">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20248K" id="ixv-337">DYAI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20248K" id="ixv-338">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="d20248K" id="ixv-339">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
